LOGIN  |  REGISTER
Compass Therapeutics

Varex Imaging Management to Participate in Upcoming Investor Conferences

May 28, 2024 | Last Trade: US$16.37 0.03 -0.18

SALT LAKE CITY / May 28, 2024 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) announced today that management is scheduled to participate in the following upcoming investor conferences.

  • Jefferies Global Healthcare Conference in New York – June 6, 2024 at 9:00am ET
  • Goldman Sachs 45th Annual Global Healthcare Conference in Miami – June 10, 2024 (1x1 only)
  • Sidoti June 2024 Virtual Small Cap Conference – June 13, 2024 at 10:45am ET

These events can be accessed at the Varex Imaging website: www.vareximaging.com/news on the dates and times listed above.

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,300 people located in North America, Europe, and Asia. For more information visit www.vareximaging.com

Terns Pharmaceuticals

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB